Fundz

CalciMedica

LA JOLLA, California, United States · Biotechnology, Healthcare

CalciMedica is a privately held, clinical stage biotechnology company with a platform focused on CRAC channel drug discovery and development for the treatment of acute and severe inflammatory diseases. The Company was founded in 2007 by Ken Stauderman, CalciMedica’s Chief Scientific Officer, and colleagues at Torrey Pines Therapeutics in San Diego and Harvard’s Center for Blood Research in Cambrid

Key facts

Headquarters
LA JOLLA, California, United States
Employees
16
Industries
Biotechnology, Healthcare
Status
Public (CALC)
Website
calcimedica.com
LinkedIn
Company page

Recent activity at CalciMedica

  • : CalciMedica Announces Resignation of CFO Stephen Bardin
  • : SEC 8-K (5.02): On October 15, 2026, Stephen Bardin, the Chief Financial Officer and principal financial officer of CalciMedica, Inc., submitted his resignation, effective immediately following the filing of the Company’s Quarterly Report on Form 10-Q for Q3 2026. Mr. Bardin's decision to resign is based on his pursuit of another professional opportunity and is not due to any disagreements with the Company. This change may impact the financial oversight of the Company as Mr. Bardin played a critical role in its financial operations.
  • : SEC 8-K (8.01): On September 30, 2026, CalciMedica, Inc. filed a prospectus supplement regarding the sale of the Company's common stock with the SEC. This supplement allows the Company to offer and sell common stock with an aggregate offering price of up to $25,000,000 as part of their at-the-market offering agreement with H.C. Wainwright & Co. established on August 11, 2023. The filing is made under the Company's shelf registration statement that was declared effective on March 11, 2026. This move may provide the Company with liquidity to fund operations and expansion efforts.
  • : SEC 8-K (8.01): On September 15, 2026, CalciMedica, Inc. received notification from the Nasdaq Listing Qualifications Department indicating that the company has regained compliance with Nasdaq's Minimum Bid Price Requirement. The company was previously notified on March 16, 2026, that it was non-compliant due to its stock trading under $1.00 for 30 consecutive business days. Following the compliance period, the company’s stock price rose to $1.00 or greater for at least 10 consecutive business days, specifically from August 31, 2026, to September 14, 2026. This compliance allows CalciMedica to continue its listing on the Nasdaq Capital Market, mitigating any potential delisting risks and aligning with its strategic operations.
  • : SEC 8-K (8.01): CalciMedica, Inc. reported in its 8-K filing that on August 31, 2026, it received a letter from the Nasdaq Listing Qualifications Department addressing its non-compliance with the $35 million market value of listed securities requirement under Nasdaq Listing Rule 5550(b)(2). The company had previously been notified on March 13, 2026, and has until September 9, 2026, to regain compliance. The company's Quarterly Report indicated stockholders' equity of $5,513,000 as of June 30, 2026, contributing to their current non-compliance status. This filing is significant as it will inform shareholders of ongoing financial compliance and potential risks related to its market listing.
  • : SEC 8-K (5.02): On August 19, 2026, CalciMedica, Inc. held its 2026 Annual Meeting of Stockholders where stockholders approved an amendment to the 2023 Equity Incentive Plan, increasing the authorized shares of common stock for issuance under the plan by 7,500,000 shares. The amendment also includes provisions for calculating the annual automatic share reserve increase based on shares issuable from convertible preferred stock and pre-funded warrants. This decision is significant as it reflects stockholder confidence in the company's growth agenda and expansion of employee compensation packages tied to equity.
  • : SEC 8-K (5.02):
  • : CalciMedica secures investment from Bering Partners II, with the fund acquiring 1,450,267 units at $0.8033 each, indicating a strategic partnership. The investment enhances Bering's stake to 6.9% with rights to Series A and Series B warrants.
  • : SEC 8-K (1.01): On June 23, 2026, CalciMedica, Inc. entered into a securities purchase agreement with several institutional and accredited investors for a private placement of 18,673,429 units. Each unit consists of either one share of common stock or one pre-funded warrant to purchase a share of common stock, alongside rights to receive Series A and Series B warrants upon stockholder approval. The purchase prices for these units are set at $0.8033 for common stock units and $0.8032 for pre-funded warrant units. Key personnel involved include CEO Rachel Leheny and Chief Business Officer Eric Roberts, both board members and significant shareholders, illustrating the strategic commitment of the company's leadership to securing necessary funds for future growth.
  • : SEC 8-K (1.01): On June 23, 2026, CalciMedica, Inc. entered into the First Amendment to its Loan and Security Agreement with Avenue Venture Opportunities Fund II, L.P. The amendment modifies the principal amount to $10,000,000 and extends the interest-only period until September 30, 2027, with amortization payments beginning October 1, 2027. Additionally, the maturity date is extended to September 1, 2029. The amendment includes a $200,000 increase in the final payment fee and alters the lender's conversion rights, allowing conversion of up to $3,000,000 into common stock or pre-funded warrants at a defined price. Significant strategic implications include easing immediate financial pressures for the Company by extending payment terms and enhancing the lender's investment flexibility.

CalciMedica funding history

DateRoundAmount
Jul 2026Series A$1.2M
Apr 2023Venture$9.1M
Apr 2023Venture$10.3M
May 2020Venture$17.2M
Aug 2019Venture$55.0M

Leadership

  • Hansoo Keyoung, Director
  • Cameron Ph.D., Director
  • Christy Ph.D., Director
  • Emmett Ph.D., Director
  • Chau Khuong, Director
  • Gerald Ph.D., Director
  • Frederic Guerard, Executive Officer, Director, Promoter
  • Cameron Wheeler, Director
  • Emmett Cunningham, Director
  • Chau Khoung, Director
  • Christy Shaffer, Director
  • Justin Hanes, Director

Verified email and direct lines for CalciMedica’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Employee benefit plans

CalciMedica files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

CalciMedica in the news

Companies similar to CalciMedica

About CalciMedica: questions and answers

What does CalciMedica do?

CalciMedica is a privately held, clinical stage biotechnology company with a platform focused on CRAC channel drug discovery and development for the treatment of acute and severe inflammatory diseases. The Company was founded in 2007 by Ken Stauderman, CalciMedica’s Chief Scientific Officer, and colleagues at Torrey Pines Therapeutics in San Diego and Harvard’s Center for Blood Research in Cambrid

Where is CalciMedica headquartered?

CalciMedica is headquartered in LA JOLLA, California, United States.

How many employees does CalciMedica have?

CalciMedica has about 16 employees.

Has CalciMedica raised funding?

Yes. Fundz has recorded 5 funding events for CalciMedica. The most recent, Series A of $1.2M, was in Jul 2026.

What is the latest news on CalciMedica?

On Oct 16, 2026, CalciMedica Announces Resignation of CFO Stephen Bardin

Is CalciMedica a public company?

Yes. CalciMedica is publicly traded under the ticker CALC.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches CalciMedica across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.